11 result(s) for 'Tonsil'
1 - 10 of 11 results for 'Tonsil'
Sort by
Show
Antigen Backgroundp16 (INK4a) (Cyclin-dependent kinase inhibitor 2A (CDKN2A)) is a tumour suppressor protein associated with cell cycle progression, specifically in the regulation of transition from G1 phase of the cell cycle in to the S phase. Oncogenic mutations in the CDKN2A gene that encodes p16 (resulting in over or under expression of the protein) is associated with a wide range of cancers and cancer precursor lesions.Disclaimerp16 is recom...
Slide 1
Hello, hello; thank you so much for that introduction. Let's get started. Oh, I'm sorry, I just need to hit this next button here. So my name is Mark Lawson.
Thank you for joining us in this webinar. I'm here to present BOND RX tips, tricks, and optimization. It's going to be a user guide from the BOND RX and chromogenic multiplexing in the research application.
Slide 2
So, my name is Mark Lawson. I'm an application specialist on the Life Sciences team at Leica Biosystems I provide technical support for the Life Sciences portfolio, including but not limited to the BOND RX, the BOND RXm, and a wide array of reagents. So I've worked in the histology field for about 15 years and in both clinical and research spaces. I started off as a histotechnologist and worked my way up...
Phenotyping Tumor Microenvironment Using DNA Barcoded Multiplex Technology Chifei Sun GSK IVIVTBIBCellular Biomarkers Collegeville, PA
I have no conflict of interests with Leica Biosystems, Ultivue and Indica Labs. – All the materials used in this presentation are for educational purpose only. – The human biological samples were sourced ethically, and their research use was in accord with the terms of the informed consents under an IRB/EC approved protocol. Statement 9/25/2020 2
Understand the complexity of tumor microenvironment and its importance in drug development – Introduce the Ultivue DNA barcoding and exchange technology for multiplex immunofluorescence – Highlight the processes of image fusion, spatial analysis and colocalization of markers on individual cells Learning...
Biomarkers
AE1/AE3 (1)
AMACR (2)
BCL6 (1)
CD163 (2)
CD20 (2)
CD3 (9)
CD4 (5)
CD68 (5)
CD8 (10)
CDX2 (2)
CK20 (5)
Ck5 (4)
...
Antigen BackgroundTIM-3 (T-cell Immunoglobulin and Mucin Domain-Containing 3, Hepatitis A Virus Cellular Receptor, HAVCR2). TIM-3 is a Type I transmembrane that can be expressed on both tumour and immune cells. It is expressed on multiple immune cells, including type 1 T helper (Th1) cells, Th17 and CD8+ T cells, Tumour Infiltrating Lymphocytes, regulatory T cells (Tregs) and innate immune cells.DisclaimerTIM-3 is recommended for the detection of...
Antigen BackgroundCTLA-4, T-cell co-receptor cytotoxic T-cell antigen-4 (CTLA-4, CD152) is a critical inhibitory regulator of T-cell immunity. CTLA-4 is expressed almost exclusively on CD4+ and CD8+ T-cells and is crucial in the maintenance of T-cell homeostasis. Expression is induced on activated T-cells, with marginal expression on resting cells. The role of CTLA-4 in regulation of T-cell activity in the tumour microenvironment indicates a pote...
Antigen Background FOXP3 (Forkhead Box Protein 3, Scurfin) is a member of the forkhead box (FOX) famly of transcription factors. These proteins are characterised by a highly-conserved forkhead DNA-binding domain. FOXP3 has an important role in immune regulation, with its effect in reducing Interleukin-2 expression causing a reduced function of T-helper cells. The role of FOXP3 in cancer is multifaceted, with roles in both tumour progression (via ...
Antigen Background LAG-3 (Lymphocyte Activation gene 3, CD223) is a 503 amino acid transmembrane protein. It plays a role in the negative regulation of cellular proliferation & activation of T-cells in a similar manner to CTLA-4 and PD-1. LAG3 plays a role in the exhaustion of T-cell responses in cancer, and is therefore the subject of extensive research in conjunction with other related immunomodulatory markers. Disclaimer LAG-3 is recommended f...
Different types of cancers frequently metastase to bone tissue. Treatment planning decisions are often based upon histology and special staining of these distant sites of disease. These decisions may rely on the outcome of immunohistochemistry, in situ...
A review of fluorochromes and the specialized microscope used in immunofluorescence techniques will begin this presentation. A typical (human skin and kidney) clinical specimen will be followed from receipt in the laboratory, through freezing, cryomicrotomy...